Ciprian Catana

Has grant

Professor

Harvard Medical School
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Dr. Ciprian Catana is an Associate Professor at Harvard Medical School, located in the United States. His research focuses on advanced imaging techniques and clinical trials related to pulmonary fibrosis and myocardial health. Recent publications include studies on collagen deposition in individuals with idiopathic pulmonary fibrosis and innovative multimodal image synthesis methods.

Recent Grants

Grant: Close

Next-Generation 3 Tesla Human MRI Scanner for Mental Health Research

Open Date: 2024-08-16

Close Date: 2026-08-15

Grant: Close

High Performance PET/CT Scanner

Open Date: 2023-05-01

Close Date: 2026-04-30

Grant: Close

MRI-compatible BrainPET Scanner

Open Date: 2022-08-01

Close Date: 2025-07-31

Grant: Close

PET-MR Imaging of pulmonary fibrosis

Open Date: 2021-07-01

Close Date: 2026-06-30

Grant: Close

Development of the Human Dynamic Neurochemical Connectome Scanner

Open Date: 2020-09-21

Close Date: 2026-05-31

Articles (18)

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Our group has shown that translocator protein (TSPO) levels, a putative marker of neuroinflammation, are increased in the brain and spinal cord of patients with chronic low back pain (cLBP). Whether neuroinflammation might be a therapeutic target for this condition is unknown. In this phase II double-blind, placebo-controlled, randomized clinical trial, we sought to evaluate whether the tetracycline antibiotic minocycline, which is commonly used as a glial inhibitor in preclinical models, has an effect on brain TSPO levels in adults with cLBP. Participants randomly received 100-mg minocycline or placebo, once a day for 2 weeks. The primary outcome was the change (pretreatment vs posttreatment) in thalamic TSPO levels, measured using [ 11 C]PBR28 positron emission tomography signal (standardized uptake value ratio) and analyzed with a mixed effect model. Secondary outcome measures included the change in Brief Pain Inventory, severity subscore. Among 60 enrolled participants, 48 completed the trial. Of these, 25 received minocycline (age [years], mean ± SD: 44.6 ± 16.9; 9 female), and 23 received placebo (49 ± 17.1; 9 female). The mean thalamic positron emission tomography standard uptake value ratio was very stable across visits in both groups, with no significant group-by-time interaction ( P = 0.956). Similarly, both groups demonstrated a comparable decrease over time in Brief Pain Inventory severity scores ( P = 0.018) and no significant group-by-time interaction ( P = 0.329). Our results suggest that minocycline, at the tested regimen, may neither reduce brain TSPO levels nor have clinically meaningful effects on clinical pain in patients with cLBP.

Year:

2025

Year:

2025

Year:

2025

For the past 20 years our research has specifically focused on developing potential therapies targeting specific properties of tumor cells that have metastasized. Although the mechanisms and triggers of metastasis are not completely understood, cancer cells exhibit the ability to break out of the primary tumor mass, travel through the circulation, and colonize a new vital organ in the process of metastasis. Of therapeutic significance, these metastatic cells are genetically and phenotypically distinct from the majority of the cells in the tumor mass serving to limit the effectiveness of those therapies whose focus is the primary tumor itself. In our earlier discovery efforts, miRNA-10b was identified as a master regulator of the viability of metastatic tumor cells. miRNA-10b not only promotes the capacity of tumor cells to migrate and invade surrounding tissue (become metastatic) but, most notably, serves as a powerful master regulator of the viability of these cells and their capacity to survive outside of the primary tumor microenvironment. Detailed cellular and preclinical mechanistic studies confirmed the existence of a miR-10b-triggered pathway that regulates the viability and proliferation of tumor cells only after they have acquired the ability to metastasize. This knowledge allowed us to develop a therapeutic strategy based on miR-10b inhibition. The specific inhibition of miR-10b was achieved using inhibitory oligonucleotides (locked nucleic acid, LNA-based antagomirs) delivered to metastatic sites by aminated dextran-coated iron oxide nanoparticles (termed TTX-MC138). Our research demonstrated that TTX-MC138 could cause complete and persistent regression of metastases in cancer models with no evidence of systemic toxicity. On the path to clinical development of TTX-MC138, we conducted critical, exploratory IND enabling studies in rats, dogs, and non-human primates with TTX-MC138. Ultimately, the information generated resulted in FDA authorization under IND163800 allowing for initiation of an ongoing microdosing Phase 0 clinical trial in patients with advanced metastatic cancer. The strategy of conducting an initial Phase 0 study was not only to assist in the identification of susceptible tumor types (or patients) but also to support future clinical efforts by providing proof of concept and quantification of delivery to clinical metastases. The Phase 0 clinical trial involves a single injection of a microdose of Cu-64 labeled TTX-MC138 which allows for direct visualization in cancer patients via PET-MR imaging, with a primary endpoint of confirming its localization (%ID/cc) to the metastatic lesions. We have now obtained initial clinical data on drug PK and accumulation in clinical metastases to the lungs, bone, and liver, as well as drug stability, metabolism, and pharmacodynamic activity. We have demonstrated TTX-MC138 uptake by bone, lung, and liver metastases, as well as tumor to blood ratios reflective of selective retention of the drug by tumor tissue. We have established that the drug has a long circulation time of 20 hrs in humans. Remarkably, even at a 100 microgram microdose, the drug showed robust PD activity with a 70% inhibition of the miR-10b target in blood over the full time course of the study. The process leading to the implementation of TTX-MC138 in the clinic is critically dependent on the innate tropism of the TTX delivery platform to tumors and represents a first step towards developing effective nucleic-acid based therapeutics against cancer. Citation Format: Zdravka Medarova, Neil Robertson, Subrata Ghosh, Hsiao-Ying Wey, Mariane LeFur, Onofrio Catalano, Ciprian Catana, Peter Caravan, Susan Duggan, Andreas Varkaris. Early Clinical Experience with TTX-MC138, a First-in-Class Therapeutic Candidate for Metastatic Breast Cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abst

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2022

Year:

2020

Collaborators (17)

Federico Turkheimer

King’s College London

UNITED KINGDOM
View details

Bernd Pichler

University of Tuebingen

GERMANY
View details

Peter Grace

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ludovica Brusaferri

Senior Lecturer

London South Bank University

UNITED KINGDOM
View details

Iris Yuwen Zhou

Assistant Professor

Massachusetts General Hospital

UNITED STATES
View details

Nicole R Zürcher

Assistant Professor

-

UNITED STATES
View details

Angel Torrado-Carvajal

Assistant Professor

Universidad Rey Juan Carlos

SPAIN
View details

Jacob Hooker

Massachusetts General Hospital

UNITED STATES
View details

Steven Stufflebeam

Associate Professor of Radiology/Medical Director

Massachusetts General Hospital

UNITED STATES
View details

Kimberly Sullivan

Research Associate Professor

Boston University School of Public Health

UNITED STATES
View details

Fabian P Schmidt

-

GERMANY
View details

J. M. Udias

Universidad Complutense de Madrid

SPAIN
View details

Jonathan R Polimeni

Stanford University

UNITED STATES
View details

Mattia Veronese

associate professor in biomedical engineering

King’s College London

UNITED KINGDOM
View details

Julia Schubert

King’s College London

UNITED KINGDOM
View details

David Izquierdo-Garcia

Massachusetts Institute of Technology

UNITED STATES
View details

Vitaly Napadow

Professor

Harvard Medical School

UNITED STATES
View details